BIOSYNTECH, INC. Inactive Instrument
BioSyntech, Inc. Share Price Other OTC
Equities
BSYI
CA09068L1031
Biotechnology & Medical Research
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2008 | 3L 2L 1.68Cr | Sales 2009 | 40.77T 29.89T 24.96L | Capitalization | 1.2Cr 88.06L 74Cr |
|---|---|---|---|---|---|
| Net income 2008 | -90L -65.98L -55Cr | Net income 2009 | -1.2Cr -87.98L -73Cr | EV / Sales 2008 | 88 x |
| Net Debt 2008 | 2L 2L 1.47Cr | Net Debt 2009 | 82.75L 60.67L 51Cr | EV / Sales 2009 | 498 x |
| P/E ratio 2008 |
-2.58
x | P/E ratio 2009 |
-0.93
x | Employees | - |
| Yield 2008 * |
-
| Yield 2009 |
-
| Free-Float | 58.8% |
More Fundamentals
* Assessed data
BioSyntech, Inc. is a Canada-based biotechnology company. The Company is developing biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. The Company's platform technology is a family of hydrogels called BST-Gel, some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offers properties for the local repair of damaged tissue such as cartilage, bone and chronic wounds and provide the benefit of avoiding invasive surgery. The Company's lead, late-stage product, BST-CarGel is undergoing an international pivotal trial.
| 1st Jan change | Capi. | |
|---|---|---|
| +29.46% | 4.95TCr | |
| +0.70% | 4.26TCr | |
| +48.83% | 4.25TCr | |
| -5.26% | 2.91TCr | |
| +12.42% | 2.66TCr | |
| -24.25% | 1.86TCr | |
| +7.26% | 1.32TCr | |
| +31.96% | 1.25TCr | |
| +23.79% | 1.21TCr |
